Proteome Sciences PLC Director/PDMR Shareholding (4746V)
14 Avril 2021 - 1:18PM
UK Regulatory
TIDMPRM
RNS Number : 4746V
Proteome Sciences PLC
14 April 2021
14 April 2021
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Richard Dennis, Chief
Commercial Officer, that on 12 April and 13 April 2021 he
purchased, in aggregate, 625,000 Ordinary Shares in the Company at
an average price of 5.22p per share. Richard Dennis now holds
625,000 Ordinary Shares in the Company, which represents
approximately 0.21% of the issued share capital of the Company.
The below notification is made in accordance with the
requirements of the UK Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Richard Dennis
----------------------------------------- --------------------------------
Reason for the notification
---------------------------------------------------------------------------
a) Position/status: Chief Commercial Officer
and Executive Director
----------------------------------------- --------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- --------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- --------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- --------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p nominal
type of instrument: value
Identification code: GB0003104196
----------------------------------------- --------------------------------
b) Nature of the transaction: Purchase of Ordinary Shares
----------------------------------------- --------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
5.29p 125,000
----------
5.23p 125,000
----------
5.23p 125,000
----------
5.14p 250,000
----------
----------------------------------------- --------------------------------
d) Aggregated information: Single transaction as in
* Aggregated volume: 4 c) above Average Volume(s)
Price
5.22p 625,000
* Price: ----------
----------------------------------------- --------------------------------
e) Date of the transaction: 12 and 13 April 2021
----------------------------------------- --------------------------------
f) Place of the transaction: London Stock Exchange,
AIM (XLON)
----------------------------------------- --------------------------------
For further information please contact:
Proteome Sciences plc
Mariola Soehngen M.D., Chief Executive Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter - Corporate Tel: +44 (0) 20 3328 5656
Finance
Tony Quirke - Sales and Corporate Broking
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSFMFFLEFSEFL
(END) Dow Jones Newswires
April 14, 2021 07:18 ET (11:18 GMT)
Proteome Sciences (AQSE:PRM.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Proteome Sciences (AQSE:PRM.GB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
